Tweets

Guselkumab FDA Approved for Pediatric Psoriasis and Psoriatic Arthritis
FDA announced yesterday that guselkumab (Tremfya) is approved for use in pediatric patients moderate to severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA) in children six years and older https://t.co/GHjCgqHaJC
Dr. John Cush @RheumNow ( View Tweet )
1 week 1 day ago

What is IPAF?
Idiopathic Interstitial Pneumonia with Autoimmune Features - or IPAF - describes patients with interstitial pneumonia with autoimmune features, but they don’t meet a diagnosis of a CTD.
https://t.co/ThU4pq27MU https://t.co/AOa5PALJst
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 week 1 day ago

🆕 ILD (Part III): clinical practice focus 🔬 Diagnostic challenges 🧑⚕️ Case-based learning 📈 Evidence & outcomes 🌍 Global perspectives ⬇️ Download & learn more: https://t.co/WhpVzAfPDD Created by @MithuRheum | For our Rheum to Breathe: ILD Campaign https://t.co/4CL9mX9D6Y
Dr. John Cush @RheumNow ( View Tweet )
1 week 1 day ago

Post hoc analysis of Gout (CARES) trial (rx w/ ULT) showed remission @ 1yr increased from 37% to 63% at yr 6. In 6 yrs, 59% achieved remission 1+ times. Remission was signif assoc w/ age, race, Hi Dz severity, comorbidities, and febuxostat treatment https://t.co/uTOkch8VW6 https://t.co/Ykc7JV6m7r
Dr. John Cush @RheumNow ( View Tweet )
1 week 2 days ago

There is no consensus on flare definition in PSA. Review of 12 #PsA studies shows flare prevalence ranged 7% to 10%, w/ incidence was 22–23%. Over 12 mos, current patient-reported flare = 10%, physician-reported flare = 7% https://t.co/2LKlnaMSyv https://t.co/0TYXiZGsSc
Dr. John Cush @RheumNow ( View Tweet )
1 week 2 days ago

UK remission rates for early RA have been stablebut there are variations. DAS study of 13 752 RA, 35% in remission - but 28% (London) to 40% (East England). Delays in referral since COVID-19. Less remission w/ youth, female, Black, hi DAS28, delayed DMARDs. longer Sxs duration https://t.co/57QlnEqBci
Dr. John Cush @RheumNow ( View Tweet )
1 week 2 days ago

Retrospective study of 259 SSc pts underwent cardiac MRI looking for primary heart involvement (pHI) - detected in 37 14%). Predictors included troponin T (OR 14.1), CRP [OR 11.2), ILD [OR 6.3), and arrhythmias https://t.co/8KTINQ5loi https://t.co/60wQAPCUJv
Dr. John Cush @RheumNow ( View Tweet )
1 week 2 days ago

Small 38 pt. RCT found that 16-wks of Mediterranean diet signif improved psoriasis PASI scores. Intervention grp had better PASI change at week 16 (−3.4 vs 0), PASI 75, and reducted hemoglobin A1c. Diet as adjunctive Rx in PsO!! https://t.co/oJnaAA8LMm https://t.co/AXxI8FWQqU
Dr. John Cush @RheumNow ( View Tweet )
1 week 3 days ago

Impact cumulative MTX on liver fibrosis? 1314 #PsA pts (age 44), 28% on MTX. Total of 44 (3%) had baseline liver fibrosis & 12% developed it over med/ 5.6 yrs. Cumulative MTX Did NOT assoc w/ liver fibrosis (OR 0.99), but high BMI & DM did (Metabolic factors) https://t.co/OSVZHskjB4
Dr. John Cush @RheumNow ( View Tweet )
1 week 3 days ago

Challenges diagnosing lung disease and ILD in pediatric patients
Children with juvenile idiopathic inflammatory myositis (JIIM) are at risk of developing lung disease, notably interstitial lung disease (ILD).
https://t.co/SClva7aqKH https://t.co/hVX5zdju5V
Dr. John Cush @RheumNow ( View Tweet )
1 week 3 days ago

2019 National Health Survey of 87,678, 21% had chronic back pain (cLBP). cLBP had more Multimorbidity 62.1%, worse activity limitation. depression, and cardiovascular disease https://t.co/LFdWr0s6tg https://t.co/R5cZSWySUK
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 week 3 days ago

RheumNow is LIVE from #ACR25 Oct 24–29.
KOL perspective videos, clinical-trial highlights, daily recaps & live streaming—all in one feed. https://t.co/fD2K4zW9Z7
Dr. John Cush @RheumNow ( View Tweet )
1 week 3 days ago